Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

Afshar, Reza Malekpour; Mollaie, Hamid Reza

doi:10.7314/apjcp.2012.13.11.5463

Cited by 5 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other mutations reported in this study have been previously reported in other countries (21, 26-28). We did not observe other reported mutations in Iran, including Q149K, L122F, N118D/T, L157M, H124Y, rtA181T, rtA181S, rtM204I, rtA181T, rtN236, and rtA181V (25,29,30).…”

Section: Discussioncontrasting

confidence: 80%

A Lamivudine/ Entacavir Resistance Mutations Among Treatment Naïve Chronic HBV Infected Patients Mashhad, Iran

Saedi

Derakhshan

Shamsian

et al. 2022

Iran J Med Microbiol

View full text Add to dashboard Cite

Background and Aim: Despite significant progress in Hepatitis B Virus (HBV) treatment, the emergence of drug resistance mutations is a main challenging health threat. The data is lacking regarding circulation mutant strains in northeastern Iran; therefore, the present study was conducted to investigate HBV reverse transcriptase (RT) inhibitors drug resistance mutations in a group of treatment naïve patients in Mashhad, Iran. Materials and Methods:In this study, 25 patients were included. The genomic DNA was extracted from serum samples, and the RT gene of HBV was amplified using specific primers. The PCR products were then subjected to gel electrophoresis and were next sent for sequencing. Finally, the sequences were analyzed using the HBVseq database, mutation list analysis software supported by Stanford University (https://hivdb.stanford.edu). Results:The mean age of the patients was 42.7±16.5. Among the patients, 56% were men. Among 23 cases (92%), no resistance mutation was observed, while 2 cases showed mutations outside the YMDD motif of viral reverse transcriptase causing Lamivudine or Entecavir resistance. The detected mutations included: rt T184A, S202I, S202H, V180I, I169L, and V173L. All sequenced samples were identified as genotype D. Conclusion:Lamivudine/Entecavir resistant variants are circulating in a minority of treatment naïve patients, which may indicate transmission of mutated stains to these patients or may be due to prolonged replication of the virus. This finding might be considered an alarm for increasing circulating mutant variants.

show abstract

Section: Discussioncontrasting

confidence: 80%

A Lamivudine/ Entacavir Resistance Mutations Among Treatment Naïve Chronic HBV Infected Patients Mashhad, Iran

Saedi

Derakhshan

Shamsian

et al. 2022

Iran J Med Microbiol

View full text Add to dashboard Cite

show abstract

“…The viral infections cause many deaths in many parts of the world. Hepatitis B virus (HBV) infection is also one of those viral diseases and a major public health problem [1]. HBV can cause a variety of diseases in humans from inactive carriers to progressive liver disease, including chronic hepatitis B, cirrhosis and hepatocellular carcinoma (HCC) [2].…”

Section: Introductionmentioning

confidence: 99%

Upregulation of Single Nucleotide Polymorphism of PD-1 Gene (rs10204525) in Chronic Hepatitis B Patients

Ghorbani¹,

Mollaei²,

Arabzadeh³

et al. 2019

Int Arch Med Microbiol

View full text Add to dashboard Cite

Background: Programmed death-1 (PD-1) is major inhibitory molecule that reduces T cell activation. PD-1 and their polymorphisms have separately been shown to be associated with hepatitis B virus (HBV) infection. Therefore, we aimed to investigate the association of PD1 polymorphisms with potential of chronic hepatitis B infection in Iranian population to do a Case-Control study. Methods: In this study HBV DNA, and PD-1 mRNA, were extracted from 60 patients with chronic hepatitis B and 60 healthy blood donors as control. HBV Viral Load, polymorphism genotype of the two groups and level expression of PD1 gene were evaluated using Real time PCR method. Results: Age mean of the control group was 40.7 ± 3.7 and 35.86 ± 11.18 year's old age for the case group. The GG allele between the two groups had the same frequency (73.3% in CHB group and 80% in healthy group). The GA allele in patients with hepatitis B (20%) was most frequent. There was a significant association between the GA allele and chronic hepatitis B infection. There was no significant relationship between the ages of the subjects with SNPrs10204525. Also, the expression of PD-1 mRNA was higher in people with hepatitis B than in healthy group. Conclusion: The results of this study showed that there is a significant relationship between the presence of rs10204525 polymorphisms in the PD-1 gene in patients with chronic hepatitis B infection and the association between the GA allele and chronic hepatitis B can be linked.

show abstract

Evaluation of HBV resistance to tenofovir in patients with chronic hepatitis B using ZNA probe assay in Kerman, southeast of Iran

Motahar

Arabzadeh

Mollaei

et al. 2016

Asian Pacific Journal of Tropical Disease

View full text Add to dashboard Cite

Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

Cited by 5 publications

References 26 publications

A Lamivudine/ Entacavir Resistance Mutations Among Treatment Naïve Chronic HBV Infected Patients Mashhad, Iran

A Lamivudine/ Entacavir Resistance Mutations Among Treatment Naïve Chronic HBV Infected Patients Mashhad, Iran

Upregulation of Single Nucleotide Polymorphism of PD-1 Gene (rs10204525) in Chronic Hepatitis B Patients

Evaluation of HBV resistance to tenofovir in patients with chronic hepatitis B using ZNA probe assay in Kerman, southeast of Iran

Contact Info

Product

Resources

About